Product Description
Dihydroergotamine belongs to the group of medicines called ergot alkaloids. It is a nasal solution used to help relieve migraine headaches. Nasal dihydroergotamine is not an ordinary pain reliever. It will not relieve any kind of pain other than throbbing headaches. (Sourced from: https://www.mayoclinic.org/drugs-supplements/dihydroergotamine-nasal-route/side-effects/drg-20063447?p=1)
Mechanisms of Action: 5-HT1D Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical,Nasal,Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Austria | Belgium | Brazil | Canada | Chile | Dominican Republic | Ecuador | France | Germany | Greece | Ireland | Italy | Korea | Morocco | New Zealand | Peru | Poland | Portugal | Russia | Slovenia | South Africa | Sweden | Taiwan | Tunisia | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Satsuma Pharmaceuticals
Company Location: SOUTH SAN FRANCISCO CA 64080
Company CEO: John Kollins
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Migraine Disorders|Migraine with Aura|Migraine without Aura
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ACTRN12623001201662 | P1 |
Completed |
Migraine Disorders |
2024-04-04 |
|
| ASCEND | P3 |
Completed |
Migraine without Aura|Migraine with Aura|Migraine Disorders |
2023-01-16 |
|
| SUMMIT | P3 |
Completed |
Migraine with Aura|Migraine without Aura|Migraine Disorders |
2022-10-13 |